Falk Gastro Info 3/2026

Solitano V et al, Am J Gastroenterol. 2026;121(2):410-423

Effectiveness and safety of advanced combination therapies in inflammatory bowel disease (IBD): This Canadian multicenter study involving patients with refractory IBD or extraintestinal manifestations reports clinical and endoscopic response rates after 12 months of advanced combination therapies of 60% and 32%, respectively, and a clinical remission rate of 30%.

Honap S et al, Clin Gastroenterol Hepatol. 2026;24(2):484-492.e7

JAK inhibitor-induced acne in inflammatory bowel disease: This large retrospective cohort study revealed a prevalence of acne in 15.9%, 4.3% and 1.9% of patients treated with upadacitinib, tofacitinib and filgotinib, respectively. 40% of patients with acne received specific medical therapies and 18% required dose reduction or discontinuation of the JAK inhibitor.

Lucas-Ruiz F et al, Gut. 2025;74(12):2058-2069

Microbial signatures as predictors of transplant outcomes: A recent study shows that microbial signatures from donor livers, detectable in organ preservation fluid, are associated with early outcomes after liver transplantation. The findings highlight the intrahepatic microbiome as a previously underrecognized factor influencing early graft function. The results suggest that microbiological profiling may help improve risk assessment and organ allocation in the future.

Lai JC et al, Gut. 2025;74(12):2050-2057

Risk-based HCC surveillance in MASLD using non-invasive tests: This study demonstrates that non-invasive markers such as the FIB-4 score and liver stiffness measurement can reliably predict hepatocellular carcinoma risk in patients with MASLD. Defined thresholds help identify those who may benefit most from surveillance, for example with FIB-4 ≥ 3.25 or elevated liver stiffness. The findings support a more targeted, risk-adapted approach to HCC surveillance rather than broad screening.

Shiha MG et al, Gut. 2026;75(3):502-510

Worldwide prevalence of self-reported non-celiac wheat sensitivity (NCGWS): Results of this meta-analysis indicate that approximately one in 10 people worldwide self-report NCGWS, with a female predominance and a significant association with psychological distress and irritable bowel syndrome.

Grover S et al, Gut. 2026;75(3):476-485

First genome-wide association study (GWAS) of idiopathic achalasia (IA): Results of this large GWAS study reveal an immune pathogenesis of IA, supporting the role of small nucleotide polymorphisms, cell types such as memory CD4 T cells within the myenteric plexus and novel disease mechanisms in IA etiopathogenesis.